In a phase II trial led by researchers from MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage, resectable non-small cell lung cancer.
Specific sequences of chemotherapy, targeted therapy, and immunotherapy yielded significantly different results, according to a study that utilized simulation models and real-world data to predict outcomes under different sequencing scenarios.
